Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation

Suzuki, Takanori; Inoue, Tomio; Matsuura, Kentaro; Kusumoto, Shigeru; Hagiwara, Shinya; Ogawa, S.; Yagi, Shusuke; Kaneko, Atsushi; Fujiwara, Kei; Watanabe, Takehisa; Aoyagi, Katsumi; Urata, Yukitomo; Tamori, Akihiro; Kataoka, Hiromi; Tanaka, Yasuhito

doi:10.1007/s00535-022-01872-w

Cited by 11 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another report, the efficacies of measuring iTACT-HBcrAg to detect HBV reactivation and to determine the initiation of NA treatment were assessed [ 64 ]. Of 44 patients with HBV reactivation enrolled in the study, 27 had quantifiable serum HBV DNA (≥1.3 logIU/mL), serum HBV DNA being unquantifiable (<1.3 logIU/mL) in the remaining 17 patients.…”

Section: A High-sensitivity Hbcrag Assay Put Into Practical Use In Japanmentioning

confidence: 99%

“…Of the 11 patients with undetectable HBcrAg by iTACT-HBcrAg at HBV reactivation and/or thereafter, 10 had unquantifiable HBV DNA and none developed HBV reactivation-related hepatitis. Taken together, iTACT-HBcrAg is suitable for monitoring HBV reactivation to determine the initiation of NA treatment [ 64 ].…”

Section: A High-sensitivity Hbcrag Assay Put Into Practical Use In Japanmentioning

confidence: 99%

“…63 In another report, the efficacies of measuring iTACT-HBcrAg to detect HBV reactivation and to determine the initiation of NA treatment were assessed. 64 Of 44 patients with HBV reactivation enrolled in the study, 27 had quantifiable serum HBV DNA (≥1.3 logIU/mL), serum HBV DNA being unquantifiable (<1.3 logIU/mL) in the remaining 17 patients. Of the 11 patients with undetectable HBcrAg by iTACT-HBcrAg at HBV reactivation and/or thereafter, 10 had unquantifiable HBV DNA and none developed HBV reactivation-related hepatitis.…”

Section: Hbv Reactivationmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Inoue¹,

Watanabe²,

Tanaka³

2023

Clin Mol Hepatol

Self Cite

View full text Add to dashboard Cite

The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for point-of-care testing (POCT) in resource-limited areas. Hepatitis B core-related antigen (HBcrAg) reflects intrahepatic covalently closed circular DNA and serum HBV DNA. Even in patients with undetectable serum HBV DNA or HBsAg loss, HBcrAg may remain detectable. Decreased HBcrAg levels are associated with reduction of the occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis B. Recently, a fully-automated, novel high-sensitivity HBcrAg assay (iTACT-HBcrAg, cut-off value: 2.1 logIU/mL) has been developed. This attractive assay has been released in Japan very recently. iTACT-HBcrAg can be useful for monitoring HBV reactivation and prediction of HCC occurrence, as an alternative to HBV DNA. Moreover, monitoring HBcrAg may be suitable for determining the therapeutic effectiveness of approved drugs and novel drugs under development. Presently, international guidelines recommend anti-HBV prophylaxis for pregnant women with high viral loads to prevent mother-to-child transmission of HBV. However, >95% of HBV-infected individuals live in countries where HBV DNA quantification is not available. Worldwide elimination of HBV needs the scaling-up of examination and medication services in resource-limited areas. Based on this situation, a rapid and easy HBcrAg assay as a POCT is valuable. This review provides the latest information regarding the clinical use of a new surrogate marker, HBcrAg, in HBV management, based on iTACT-HBcrAg or POCT, and introduces novel agents targeting HBV RNA/protein.

show abstract

Section: A High-sensitivity Hbcrag Assay Put Into Practical Use In Japanmentioning

confidence: 99%

Section: A High-sensitivity Hbcrag Assay Put Into Practical Use In Japanmentioning

confidence: 99%

Section: Hbv Reactivationmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Inoue¹,

Watanabe²,

Tanaka³

2023

Clin Mol Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results showed that iTACT-HBcrAg had a significantly higher detection rate than HBsAg-HQ (96% vs. 52%, respectively) and suggest that the HBcrAg level may become a surrogate marker for HBV reactivation [99]. Recently, the performance of iTACT-HBcrAg has been compared with that of a high-sensitivity HBs antigen assay system (iTACT-HBsAg) using samples from patients with HBV reactivation, indicating a higher sensitivity of iTACT-HBcrAg than iTACT-HBsAg (96.3% vs. 88.9%) [100].…”

Section: Hbv Reactivation and Hbcragmentioning

confidence: 99%

Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen

Yano,

Sato,

Imanishi

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Currently, hepatitis B virus (HBV) core antibody (anti-HBc antibody) and HBV core-related antigen (HBcrAg) are widely used as serum markers for diagnosis based on the HBV core region. This review focused on anti-HBc antibodies and HBcrAg and aimed to summarize the clinical significance of currently used assay systems and the issues involved. While anti-HBc is very significant for clinical diagnosis, the clinical significance of quantitative assay of anti-HBc antibody has been reevaluated with improvements in diagnostic performance, including its association with clinical stage and prediction of carcinogenesis and reactivation. In addition, concerning the new HBcrAg, a high-sensitivity assay method has recently been established, and its diagnostic significance, including the prediction of reactivation, is being reevaluated. On the other hand, the quantitative level of anti-HBc antibody expressed in different units among assay systems complicates the interpretation of the results. However, it is difficult to standardize assay systems as they vary in advantages, and caution is needed in interpreting the assay results. In conclusion, with the development of highly sensitive HBcrAg and anti-HBc antibody, a rapid and sensitive detection assay system has been developed and used in clinical practice. In the future, it is hoped that a global standard will be created based on the many clinical findings.

show abstract

“…Suzuki et al. reported that iTACT‐HBcrAg provided positive results before HBV DNA positivity in 26 of 27 patients with HBV reactivation and could be quantified in 15 of 27 patients 11 . Taken together, iTACT‐HBcrAg represents a useful option for diagnosing early‐stage HBV reactivation and deciding on the safe cessation of NA treatment in patients with resolved HBV infection after reactivation.…”

mentioning

confidence: 99%

Toward the accumulation of evidence for a novel high‐sensitivity hepatitis B core‐related antigen assay in patients with hepatitis B virus infection

Joshita

2022

Hepatology Research

View full text Add to dashboard Cite

Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation

Cited by 11 publications

References 26 publications

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen

Toward the accumulation of evidence for a novel high‐sensitivity hepatitis B core‐related antigen assay in patients with hepatitis B virus infection

Contact Info

Product

Resources

About